Seizert Capital Partners LLC Raises Position in United Therapeutics Co. (NASDAQ:UTHR)

Seizert Capital Partners LLC raised its position in United Therapeutics Co. (NASDAQ:UTHR - Free Report) by 59.2% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 38,906 shares of the biotechnology company's stock after buying an additional 14,465 shares during the quarter. Seizert Capital Partners LLC owned about 0.09% of United Therapeutics worth $13,942,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently made changes to their positions in UTHR. Nicollet Investment Management Inc. raised its holdings in shares of United Therapeutics by 1.1% during the 3rd quarter. Nicollet Investment Management Inc. now owns 5,833 shares of the biotechnology company's stock worth $2,090,000 after buying an additional 61 shares in the last quarter. Archer Investment Corp bought a new position in United Therapeutics in the 3rd quarter valued at approximately $283,000. Oppenheimer & Co. Inc. grew its stake in shares of United Therapeutics by 20.9% in the third quarter. Oppenheimer & Co. Inc. now owns 6,248 shares of the biotechnology company's stock worth $2,239,000 after purchasing an additional 1,078 shares during the last quarter. Chase Investment Counsel Corp acquired a new stake in United Therapeutics in the third quarter valued at $492,000. Finally, Victory Capital Management Inc. raised its position in United Therapeutics by 21.9% during the 3rd quarter. Victory Capital Management Inc. now owns 186,819 shares of the biotechnology company's stock worth $66,947,000 after purchasing an additional 33,599 shares during the last quarter. 94.08% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In other news, COO Michael Benkowitz sold 15,000 shares of the company's stock in a transaction that occurred on Thursday, November 7th. The stock was sold at an average price of $401.44, for a total value of $6,021,600.00. Following the completion of the transaction, the chief operating officer now directly owns 2,577 shares of the company's stock, valued at $1,034,510.88. This represents a 85.34 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director Judy D. Olian sold 1,750 shares of United Therapeutics stock in a transaction on Monday, November 11th. The stock was sold at an average price of $412.48, for a total value of $721,840.00. Following the sale, the director now owns 5,655 shares in the company, valued at $2,332,574.40. This trade represents a 23.63 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 113,396 shares of company stock worth $42,175,418 over the last 90 days. 11.90% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

A number of equities research analysts have commented on the company. The Goldman Sachs Group upped their price target on United Therapeutics from $243.00 to $302.00 and gave the company a "neutral" rating in a research report on Friday, November 1st. Wells Fargo & Company upped their target price on United Therapeutics from $350.00 to $380.00 and gave the company an "overweight" rating in a report on Tuesday, August 20th. HC Wainwright lifted their target price on shares of United Therapeutics from $400.00 to $425.00 and gave the stock a "buy" rating in a research note on Thursday, October 31st. Oppenheimer increased their price target on United Therapeutics from $575.00 to $600.00 and gave the stock an "outperform" rating in a report on Thursday, October 31st. Finally, LADENBURG THALM/SH SH lifted their price objective on United Therapeutics from $319.00 to $344.00 and gave the stock a "buy" rating in a research report on Thursday, October 31st. One analyst has rated the stock with a sell rating, two have assigned a hold rating, twelve have assigned a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average price target of $370.86.

United Therapeutics Stock Down 6.0 %

UTHR stock traded down $23.02 during midday trading on Friday, reaching $363.25. 619,978 shares of the company's stock traded hands, compared to its average volume of 371,282. United Therapeutics Co. has a 52 week low of $208.62 and a 52 week high of $417.82. The company has a market cap of $16.22 billion, a price-to-earnings ratio of 15.95, a P/E/G ratio of 1.06 and a beta of 0.56. The firm's fifty day moving average price is $362.93 and its 200-day moving average price is $328.17.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last posted its earnings results on Wednesday, October 30th. The biotechnology company reported $6.39 earnings per share for the quarter, topping analysts' consensus estimates of $6.16 by $0.23. The company had revenue of $748.90 million for the quarter, compared to analyst estimates of $722.62 million. United Therapeutics had a net margin of 40.31% and a return on equity of 19.22%. The firm's revenue was up 22.9% compared to the same quarter last year. During the same quarter in the prior year, the business posted $5.38 EPS. Analysts forecast that United Therapeutics Co. will post 25.1 earnings per share for the current year.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.